Cancer is one of the greatest dangers to human wellbeing and survival. A key barrier to effective cancer therapy is development of resistance to anti-cancer medications. In cancer cells, the AAA+ ATPase family member thyroid hormone receptor interactor 13 (TRIP13) is key in promoting treatment resistance. Nonetheless, knowledge of the molecular processes underlying TRIP13-based resistance to anticancer therapies is lacking. The present study evaluated the function of TRIP13 expression in anticancer drug resistance and potential methods to overcome this resistance. Additionally, the underlying mechanisms by which TRIP13 promotes resistance to anticancer drugs were explored, including induction of mitotic checkpoint complex surveillance system malfunction, promotion of DNA repair, the enhancement of autophagy and the prevention of immunological clearance. The effects of combination treatment, which include a TRIP13 inhibitor in addition to other inhibitors, were discussed. The present study evaluated the literature on TRIP13 as a possible target and its association with anticancer drug resistance, which may facilitate improvements in current anticancer therapeutic options.
anticancer drug resistancethyroid hormone receptor interactor 13combination therapyNational Natural Science Foundation of China82100557Science Foundation of NantongJC2021018Large Instruments Open Foundation of Nantong UniversityKFJN2375The present study was supported by National Natural Science Foundation of China (grant no. 82100557), Science Foundation of Nantong (grant no. JC2021018), and Large Instruments Open Foundation of Nantong University (grant no. KFJN2375).Introduction
Thyroid hormone receptor interactor 13 (TRIP13) is a member of the AAA+ ATPase family able to generate mechanical stresses through ATP hydrolase activities (1). TRIP13 was initially identified as a protein that interacts with the E1 protein of the human papillomavirus (2). In 1999, TRIP13 was found to be required for the meiotic checkpoint in yeast (3). Studies have showed involvement of TRIP13 in meiotic recombination and DNA repair in several organisms, including rice (4), yeast (5), Drosophila melanogaster (6), Caenorhabditis elegans (7) and mice (8–10). Additionally, it has been identified as a constituent of the spindle assembly checkpoint (SAC) pathway (11–13), which is involved in the accurate segregation of chromosomes (14). TRIP13 [and its homolog pachytene checkpoint 2 (PCH2) is an AAA+ ATPase that produces homohexamers and uses ATP as a substrate (3,8,9, 15–19). PCH2 binds to Hop1 and alters its structure, which displaces Hop1 from DNA (20). Hydrolysis of ATP by TRIP13/PCH2 provides energy necessary to undergo conformational changes that exert mechanical force on Hop1 (21). In addition to its role as a kinetochore protein, TRIP13/PCH2 interacts with the p31comet protein, which is responsible for gene silencing (11). TRIP13/PCH2 is linked to various malignancies due to its involvement in ensuring proper biorientation of chromosomes during mitosis; TRIP13 has been shown to be overexpressed in a number of malignancies, including colorectal (22–24), head and neck (25), breast (26,27), lung (28–30), liver (31,32) and prostate cancer (33,34), multiple myeloma (35), bladder cancer (36,37) and human chronic lymphoblastic leukemia (38). Importantly, overexpression of TRIP13 promotes advancement of head and neck squamous cell carcinoma (HNSCC) (25) and lung adenocarcinoma (39). Depletion of TRIP13 or suppression of its activity has been demonstrated to diminish tumor development in head and neck and colon cancer and hepatocellular carcinoma (HCC) (32,40). TRIP13 also serves an essential role in the survival and spread of tumor stem cells in cutaneous melanoma (41), prostate cancer (33) and lung adenocarcinoma (39). Based on these findings, TRIP13 serves a key role in tumor development.
Effective cancer therapy is hampered significantly by the development of resistance to anticancer medications. Overexpression of TRIP13 has been linked to decreased sensitivity to anticancer medicines (such as bortezomib and cisplatin) (25,42). TRIP13 facilitates development of nedaplatin resistance in esophageal squamous cell carcinoma (43). In addition, synergistic anti-HCC efficacy is achieved by mixing TRIP13 inhibitor DCZ0415 with the PARP1 inhibitor olaparib (44). Therefore, TRIP13 is involved in drug resistance in cancer cells. The present study evaluated the function of TRIP13 expression in anticancer drug resistance and potential methods to overcome this resistance. Furthermore, the present study explored the underlying mechanism of targeting TRIP13 to overcome anticancer drug resistance and summarized the roles TRIP13 plays in cancer treatment. The present study also reviewed the effects of combination treatment, which include a TRIP13 inhibitor in addition to other inhibitors.
Structure and biological functions of TRIP13
The structure of human TRIP13, ATP-bound form (45) is shown in Fig. 1. Additionally, TRIP13/PCH2 exhibits kinetochore protein activity by interacting with the silencing protein p31comet (11).
TRIP13/PCH2 has been shown to have a role in mitosis, namely in the transition from metaphase to anaphase, as well as the SAC (19). It also releases anaphase-promoting complex (APC) from checkpoint inhibition (19). Before anaphase, the cell must make sure its chromosomes are appropriately organized and bioriented for separation of sister chromatids. Numerous proteins such as spindle checkpoint, securin and cyclin B, are needed for this process to maintain accurate timing and reliable separation. The activation of the APC is required for mitosis. Protein CDC20, which is typically suppressed by the mitotic checkpoint complex (MCC), activates the APC. The TRIP13-related gene Mad2 exists in two isoforms, the open (O-) form and the closed (C-) form (19). O-Mad2 changes into C-Mad2 when kinetochores detach and C-Mad2 may then hook onto CDC20 and sequester it, blocking mitotic progression (46). MCC must be disassembled, and this process is mediated by p31comet (47). This is hypothesized to take place in part via structural mimicry as p31comet has structural similarities to C-Mad2 (48). Nevertheless, ATP is needed for this step. TRIP13 uses p31comet as an adaptor protein to convert C-Mad2 into O-Mad2, then induces activation of the SAC and the formation of the MCC. To conclude, TRIP13/PCH2 is key for SAC activation and MCC formation.
Similarly, TRIP13/PCH2 is also involved in the G2/prophase stage of meiosis (3). TRIP13 affects the frequency of double-strand breaks (DSBs) promoting homology-directed repair, while suppressing non-homologous end joining and translesion synthesis. Homologous recombination following these breaks needs a protein complex to shape and direct the correct pairing of chromosomes. PCH2 gene in budding yeast is necessary for the meiotic checkpoint that inhibits chromosomal segregation when recombination and chromosome synapsis are impaired (3). TRIP13 is necessary for the creation of the synaptonemal complex (SC), which that builds chromosome pairs. In meiocytes lacking TRIP13, pericentric synaptic forks are more common, crossovers are reduced and chiasma (the site of contact between homologous chromosomes) distribution is disrupted (9). SC synthesis necessitates the elimination of HORMA domain family proteins (HORMADs) during meiosis. PCH2 is required for SC formation to remove Hop1 from chromosomes (49). In mouse spermatocytes, TRIP13 facilitates depletion of other HORMADs, including HORMAD1 and HORMAD2 (10). These findings demonstrate a key dynamic function for TRIP13/PCH2 in removal of several proteins during SC formation and subsequent meiosis.
Implications of TRIP13 in cancer
HNSCC exhibits TRIP13 overexpression, which promotes proliferation and invasion (25). Overexpression of both TRIP13 and Mad2 are associated with various types of cancer, including multiple myeloma (42), head and neck cancer (25), colorectal cancer (22–24), chronic lymphocytic leukemia (50), lung adenocarcinoma (39) and prostate cancer (33). Overexpression of TRIP13 attenuates the mitotic delay caused by Mad2 overexpression, but downregulation of TRIP13 compounds the effects of Mad2 overexpression. In addition, downregulating TRIP13 and overexpressing Mad2 suppresses proliferation in cells and tumor xenografts, suggesting therapeutic potential for inhibition of TRIP13 (47). Mad2 promotes drug resistance in ovarian cancer (51). The expression of TRIP13 is markedly increased in epithelial ovarian cancer (EOC) cell lines (SKOV-3, HEY and OVCAR-3) compared with normal ovarian cell lines (52). Additionally, knockdown of TRIP13 in EOC cells inhibits cell proliferation, decreases cell invasion and migration and stimulates apoptosis (52). This demonstrates that TRIP13 promotes the development of tumor cells and may be a potential target for tumor therapy.
TRIP13 and anticancer drug resistance
Anticancer regimens have the potential to kill most cancer cells at first, but some malignant cells survive because they have either already developed mechanisms of drug resistance (intrinsic resistance) or have acquired them through random mutation and genetic alteration (acquired resistance). Resistance mechanisms include: Decreased expression or dysfunction of influx drug transporters, increased activity of multidrug-resistant (MDR) efflux pumps of the ATP-binding cassette (ABC) superfamily, such as P-glycoprotein, multidrug resistance associated protein 1 (MRP1) and breast cancer resistance protein (ABCG2) (53), qualitative and quantitative changes in the drug target and drug sequestration within intracellular compartments. MDR efflux pumps remove numerous anticancer medications from cancer cells or store them in organelles such as lysosomes, where they are inaccessible to the cell target sites (54). The emergence of resistance to anticancer drugs is associated with genomic instability, which may include mutations, amplifications, deletion and/or translocations (55). MDR is caused by a combination of variables, including genetics (gene mutations, amplification and epigenetic modifications), growth hormones and higher DNA repair ability (56). According to Vasan et al (57), the primary factors that determine treatment resistance include: Tumor burden and growth dynamics; tumor heterogeneity; physical barriers; the immune system and the tumor microenvironment. All of these factors contribute to the diminished effectiveness of the medications used to treat the tumor.
TRIP13 expression is shown to be higher in samples from patients with multiple myeloma compared with control samples (42,58). Overexpression of TRIP13 is linked to decreased sensitivity to bortezomib and cisplatin (25,42,59). TRIP13 is shown to be responsible for the development of nedaplatin resistance in esophageal squamous cell carcinoma (43). Furthermore, considering the role of cisplatin (60–62) and PARP (63–65) inhibitors in the treatment of ovarian cancer, further study is needed to elucidate the role of TRIP13 in treatment-induced drug resistance caused by cisplatin and PARP therapy. These aforementioned results suggest a connection between elevated TRIP13 levels and drug resistance.
Targeting TRIP13 for overcoming anticancer drug resistance
Targeting TRIP13 is a potential strategy for overcoming drug resistance. Inhibiting TRIP13 makes HNSCC cells more sensitive to effects of radiation and chemotherapy (25). Recent research found that TRIP13−/− HCC cells are more vulnerable to the effects of chemotherapy than normal HCC cells (44). DCZ0415 may stimulate antimyeloma activity in primary cells generated from individuals with myeloma who are resistant to several drugs (35). Inhibition or depletion of TRIP13 may thus constitute a viable approach to circumventing resistance that anticancer drugs cause.
Underlying mechanism of TRIP13-mediated anticancer drug resistance
There are primarily three molecular mechanisms involved in TRIP13-mediated drug resistance. These mechanisms include promoting chromosomal instability, enhancing autophagy and modulating the tumor microenvironment (Fig. 2).
TRIP13 promotes drug resistance by causing chromosome instability
Previous studies have suggested that SAC is a universal safeguard that guarantees the integrity of chromosomal separation in cell division (66–68). Multiple malignancies exhibit overexpression of SAC proteins, which is linked to chromosome instability (CIN) in tumors (69–71). Additionally, telomere dysfunction (72–74) and faulty DNA repair mechanism response (75) contribute significantly to CIN in cancer. Not only does CIN serve a role in the origin, maintenance and growth of tumors, but it also stimulates the development of treatment resistance in cancer cells. TRIP13 is associated with CIN in human malignancies such as multiple myeloma (12,76,77) and treatment resistance. Previous studies have documented that TRIP13 plays a role in the induction of CIN and drug resistance via SAC signaling and modulating DNA damage repair (25,42,43,58,78).
TRIP13 induces drug resistance via inducing the dysfunction of MCC surveillance system
MCC, also known as SAC effector (79), is made of the proteins Mad2, BubR1/Mad3 and Bub3, in addition to CDC20 (68,80,81). Mis-segregation of chromosomes and failure to stop in mitosis may result from malfunctions in the MCC monitoring system. Both of these contribute to the formation of human tumors as well as medication resistance in cancer (82). Subcellular localization research demonstrates that TRIP13 co-localizes with Mad2 at kinetochores and interacts with p31comet, a Mad2-binding HORMA-domain protein that negatively controls SAC localization to kinetochores in prometaphase. When TRIP13 is overexpressed, Mad2 protein levels are reduced (42). Mad2 forms a compound with APC/cyclosome (APC/C) when the MCC monitoring system is activated. This prevents degradation of securin and cyclin B1, which ultimately leads to arrest of the cells in the prometaphase phase of the cell cycle (83). Resistance to paclitaxel is associated with a weaker spindle checkpoint in conjunction with lower expression of Mad2 (84). Through activation of the Akt signaling cascade, TRIP13 ubiquitinates and degrades the checkpoint surveillance protein Mad2, which further results in damaged checkpoint surveillance and subsequent drug resistance (42). Inhibition of PI3k/Akt may partially rescue TRIP13-induced drug resistance to bortezomib (42). The aforementioned studies indicate that TRIP13/Mad2 axis, via activating PI3K-Akt signaling pathway, leads to damage to the checkpoint surveillance system and subsequent anticancer drug resistance. Hence, TRIP13-induced anti-apoptosis action and dysfunction in MCC surveillance system contribute to chromosome instability, leading to drug resistance in cancer cells.
TRIP13 induces drug resistance by promoting DNA repair
To prevent genomic instability in the host, DNA damage response and repair mechanisms have been conserved throughout evolution (85) of both prokaryotes and eukaryotes. In mammalian cells, dysregulation of proteins involved in these processes may increase genomic changes, which lead to genomic instability, a well-established hallmark of cancer (86,87). There has been emergence of new and promising techniques for targeting the DNA damage response and repair pathways to increase cancer cell sensitivity to existing therapeutic drugs (88). Targeting DNA damage is signaling and repair may interrupt the compensatory activation of DNA repair pathways that may function as a drug resistance mechanism. For example, targeting DNA repair has become a legitimate therapeutic approach. This method uses PARP inhibitors to treat breast, ovarian, pancreatic and prostate cancers that have DNA repair deficiencies (89–95). Clinical research and development of small compounds that target key components of the DNA damage response and repair pathways, including DNA-dependent protein kinase (DNA-PK), ataxia telangiectasia mutated (ATM) and Rad3-related kinase (ATR), ATM and checkpoint kinase 1 (CHK1), have been accelerated (96). In addition, accurate targeting of these key molecules offers the possibility of using biomarkers of DNA repair deficiency to choose the most effective therapy for each individual patient to achieve the highest possible therapeutic index (96).
Recent research has provided support for the hypothesis that TRIP13-induced anti-apoptosis may contribute to drug resistance in cancer cells (97). This is because one of the primary strategies anticancer medications utilize to trigger cell death is induction of apoptosis. When TRIP13 is overexpressed, cancer cells are less sensitive to bortezomib and cisplatin (25,42). When multiple myeloma cells transfected with TRIP13 are treated with bortezomib and etoposide, cell viability experiment indicates that the number of viable tumor cells is greater in the TRIP13-transfected cells compared with control cells (42). Comparatively, HNSCC cells that overexpress TRIP13 display a decreased sensitivity to cisplatin when compared with control cells (25). Therefore, TRIP13 plays a role in the development of drug resistance in cancer cells. When treated with increasing doses of bortezomib, TRIP13-overexpressing ARP1 and OCIMy5 multiple myeloma cell lines are less likely to undergo apoptosis and better able to withstand the cytotoxic effects compared with cells transfected with empty vectors. In TRIP13-overexpressing ARP1 multiple myeloma cell line, the G2/M cell cycle arrest induced by bortezomib is consistently suppressed compared with control cells (42). In addition, TRIP13 small interfering (si)RNA knockdown in multiple myeloma cells eliminates doxycycline treatment resistance and triggers apoptosis both in vitro and in a mouse model of xenograft myeloma (35,42). In ARP1 and OCIMy5 multiple myeloma cells, downregulation of TRIP13 leads to an increase in levels of cleaved PARP and activation of caspase 3, both of which indicate a potential role for knockdown of TRIP13 in inhibiting the apoptotic pathway (42). Similarly, in human chronic lymphocytic leukemia, microarray data evaluated using the ‘canonical pathway’ module of Ingenuity route analysis reveal that TRIP13 participates in numerous apoptosis-associated pathways, including ‘induction of apoptosis by HIV1’, ‘p53 signaling’ and ‘PPAR signaling’ (50). In addition, knocking down TRIP13 causes a notable increase in the activity of caspase 3/7 in Granta-519 and JVM-2 B cell lymphocytic leukemia cell lines (50). The modulation of the c-Myc/TRIP13/p53 upregulated modulator of apoptosis (PUMA) axis is the mechanism by which TRIP13 serves a role in the development of chronic lymphocytic leukemia (50). In HNSCC, suppression of TRIP13 also induces cell cycle arrest (25). In cells transfected with TRIP13 siRNA, there is a greater accumulation of phosphorylated histone H2A histone family member X (the marker of DSBs) (25). According to western blot analysis, DSBs caused by TRIP13 siRNA occur prior to apoptosis (25). These results provided compelling evidence that TRIP13 increase DNA repair, which in turn leads to treatment resistance.
TRIP13 induces drug resistance by enhancing autophagy
Autophagy is a natural method of cell survival that is effectively employed by tumor cells to prevent cell death and generate drug resistance (98–100). Both of these may be accomplished by tumor cells via autophagy, a macromolecular process in which cells break down and recycle intracellular substrates and damaged organelles to reduce cell stress caused by factors such as nutritional deficiency, hypoxia, irradiation and cytotoxic chemicals. When cancer is in the early stages, autophagy has been shown to protect against malignant disease; nevertheless, transformed cells exhibit increased autophagy to promote survival, proliferation and metastasis (101–103). Although the precise function of autophagy in cell death and survival remains unclear, autophagy is enhanced in cancer cells exposed to stressful situations, such as anticancer treatment, which may result in anticancer drug resistance (104–106). Previous research examined TRIP13 role in autophagy by treating cells with DMSO (control), gefitinib (an autophagy agonist) and 3-methyladenine (3-MA; an autophagy inhibitor) (107); TRIP13 induces autophagy in non-small cell lung cancer (NSCLC) cells, shown by an increase in the number of LC3B (autophagy marker)-positive puncta seen by immunofluorescence examination (107). Overexpression of TRIP13 in NSCLC cells leads to an increase in LC3B and decrease in autophagy marker P62 expression (107). The opposite effects are seen in tumor cells when TRIP13 expression is suppressed (107). All of the aforementioned effects are mitigated by the gefitinib therapy, but 3-MA has the opposite effect (107). Therefore, TRIP13 may be responsible for inducing gefitinib resistance in NSCLC cells via increasing autophagy (107). Therefore, TRIP13 can be used as a biomarker and therapeutic target autophagy for overcoming drug resistance.
TRIP13 induces drug resistance by preventing immune clearance
The tumor microenvironment, which comprises immune cells, stroma and vasculature, may promote drug resistance via numerous methods, including inhibiting immune clearance of tumor cells, preventing drug absorption and increasing paracrine growth factors, to promote cancer cell development (108). DCZ0415 prevents proliferation inhibition of multiple myeloma cells even in the presence of bone marrow stromal cells and the cytokines IL6 and IGF1 in a cellular experiment that mimics multiple myeloma in its microenvironment (35). In addition to cytotoxicity against multiple myeloma cells, DCZ0415 also targets the bone marrow microenvironment and overcomes the proliferative effects on bone marrow stromal cells (35).
Additionally, suppression of TRIP13 stimulates an anticancer immune response by increasing production of cytotoxic mediators. Recent studies show that TRIP13 inhibition promotes the invasion of CD3+, CD4+ and CD8+ T cells (35). DCZ0415 considerably increases the production of cytotoxic mediators such as granzyme B, perforin and IFN-γ, which may contribute to the cytotoxic effect against murine MC38 cells. In addition, blocking immunological checkpoints, such as PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), in tumors treated with DCZ0415 has the potential to increase cytotoxicity and regression of the tumor (109). Hence, decreased expression of TRIP13 stimulates immune responses in the microenvironment of the tumor, which may help overcome drug resistance to anticancer medications.
Combination therapy for overcoming anticancer drug resistance
DNA DSBs and DNA damage responses induced by certain anticancer drugs, such as example, β-emitter iodine-131, O-6-methylguanine-DNA methyltransferases and cisplatin, make cancer cells more vulnerable to further treatment (110). DNA damage response followed by effective repair of DSBs is key to maintain genomic integrity. On the other hand, in cancer, the repair of anticancer agent-induced DSBs via the non-homologous end joining (NHEJ) or homologous recombination (HR) repair pathways enhances treatment resistance and recurrence in patients (111). According to recent research, TRIP13 improves NHEJ repair and generates treatment resistance in head and neck cancer via binding to NHEJ proteins Ku protein with molecular weight of 70 KDa (KU70, encoded by the X-ray repair cross-complementing protein 6 gene located on chromosome 22), Ku protein with molecular weight of 80 KDa, (KU80,encoded by the X-ray repair cross-complementing protein 5 gene on chromosome 2) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) (25). Additionally, GFP-based reporter experiment demonstrates that DCZ0415 inhibits DNA repair by the NHEJ repair pathway (35). Hence, combining TRIP13 inhibitor with other inhibitors may be an option to overcome anticancer drug resistance (Table I).
In addition, the upregulation of the TRIP13-mediated NHEJ repair pathway is the cause of the resistance to anticancer drugs (such as bortezomib and cisplatin). Therefore, cancer cells that have high levels of TRIP13 expression will be more susceptible to DNA-PKcs inhibitor than cancer cells with low levels of TRIP13 expression (25). Banerjee et al (25) showed that tumor cells that overexpress TRIP13 are more sensitive to the DNA-PKcs inhibitor Nu7026 (25). Hence, combining the TRIP13 inhibitor with DNA-PKcs inhibitor may be an effective treatment approach for TRIP13-mediated drug resistance.
Synergistic effects of DCZ0415 and PARP1 inhibitors
Anticancer drug resistance is partly attributed to TRIP13-induced DNA damage (25). Therefore, combining TRIP13 inhibitor with inhibitors against DNA repair proteins may overcome drug resistance (25). Synergistic effects of DCZ0415 and olaparib on increasing anticancer activity have been demonstrated in HCC cells (44). Specifically, in HCC cell lines, combination groups treated with DCZ0415 and olaparib show greater growth suppression compared with single-treatment groups, suggesting that this strategy may represent a viable therapeutic option for HCC (44). Furthermore, Clairmont et al (78) and Sarangi et al (112) demostrate that BRCA1−/− cells overexpressing TRIP13 or p31comet develop resistance to the PARP inhibitor Olaparib, and this resistance results from the reactivation of homologous recombination (HR)-mediated DNA repair owing to decreased Shieldin complex levels (113). Therefore, for individuals with BRCA1-deficient malignancies who acquire resistance to PARP medicines, blocking TRIP13/p31comet-mediated Shieldin disassembly may be a viable therapy option.
Synergistic effects of TRIP13 depletion and aurora kinase inhibitors
Ghosh et al (97) show low Rb levels drive sensitivity to aurora kinase inhibitors in human papillomavirus (HPV)-positive cancers (97). Mitotic kinases, in particular, aurora B (114) and A (114), are essential for maintenance of tumors that have loss-of-function RB1 mutations. Inhibition of Rb pathway activity upregulates MCC gene expression, which may lead to chromosomal instability and prolonged mitotic phase of the cell cycle (77,116). In patients with HNSCC, the expression of Bub1B and mitotic arrest deficient 2-like 1 (MAD2L1) is greater in HPV-positive tumors than in HPV-negative tumors. Depletion of Bub1B, as revealed by Gong et al (113), partly protects Rb-deficient SCLC cells from apoptosis produced by aurora kinase A inhibition. In a similar manner, knockdown of MAD2L1 and Bub1B significantly decreases the sensitivity to aurora kinase inhibitors in treatment of HPV-positive squamous carcinoma (97), while MAD2L1 regulator TRIP13 is depleted, which leads to an increase in the sensitivity to aurora kinase inhibitors for the treatment of HPV-positive cancers. If mitotic checkpoint gene MAD2L1 is overexpressed in HPV-positive cells and these cells need TRIP13 and aurora kinase activity to maintain mitotic fidelity, combined suppression of TRIP13 and aurora kinase activity may cause cancer cells to undergo irreversible mitotic arrest, DNA damage and death. According to previous research, the combination of TRIP13 depletion and aurora kinase inhibition leads to increased apoptosis compared with specific inhibition of a single route in HPV-positive tumors (97). Therefore, overexpression of TRIP13 makes cancer cells resistant to aurora kinase inhibitors, which are used in the treatment of HPV-positive squamous carcinoma. This resistance is induced by cancer cell ability to retain their mitotic fidelity. The combined therapeutic benefits of inhibiting TRIP13 and aurora kinase may be a potential technique for treating individuals with malignancies caused by Rb pathway abnormalities.
Discussion
TRIP13/PCH2 is associated with a number of malignancies as it ensures proper alignment of chromosomes during mitosis. As a result, TRIP13 may be a target for the development of an anticancer medication. In addition, overexpression of TRIP13 is associated with decreased susceptibility to bortezomib and cisplatin (25,42). In esophageal squamous cell carcinoma, TRIP13 causes nedaplatin resistance (43). In addition, combination of DCZ0415 with olaparib results in a synergistic effect on the activity of HCC (44). Thus, TRIP13 serves a role in cancer cell drug resistance.
To determine how TRIP13 contributes to the development of anticancer drug resistance, it is vital to research the mechanism that controls the regulation of TRIP13 expression. In perihilar cholangiocarcinoma cells, c-Myc stimulates the transcription of TRIP13 (117). In addition, transcription factor specificity protein 1 (SP1) serves a role in controlling the amount of TRIP13 that is expressed (44). TRIP13 expression is drastically reduced by SP1 inhibition or knockdown, whereas overexpression of SP1 notably increases TRIP13 expression (44). However, it is unclear whether c-Myc or SP1 are involved in development of TRIP13-mediated drug resistance. Because of this, identifying the transcription factors that govern expression of TRIP13 is required, as well as genes controlled by TRIP13, which may to act as targets for the development of cancer treatment.
Numerous studies (34,118–120) have shown that microRNAs (miRNAs) directed against TRIP13 suppress or increase proliferation of cancer cells. Cancer may be treated using miRNA mimics or inhibitors, which can also circumvent resistance to anticancer medications (121). To facilitate development of new treatment regimens, for example, the combination of TRIP13 and immune check point inhibitors, it is necessary to have a better understanding of the effects of miRNAs and TRIP13-mediated drug resistance on immune responses in the tumor microenvironment.
To create anticancer treatments that are effective for people with cancer with high levels of TRIP13, it is necessary to identify new TRIP13-binding proteins and the TRIP13 binding domain. There is a possibility that peptides with a structure identical to the binding domain of TRIP13 may facilitate overcoming resistance to anti-cancer medications. For example, TRIP13 binds to ubiquitin-specific protase-7 (USP7), then TRIP13-induced resistance to proteasome inhibition can be overcome by a USP7 inhibitor (25,42,59).
Additionally, the microenvironment of a tumor comprises innate and adaptive immune cells (B and T, dendritic and myeloid-derived suppressor cells and M1/2 macrophages), as well as cancer cells and endothelial cells and cancer-associated fibroblasts. The tumor microenvironment is essential for the development and progression of cancer. There is evidence that interactions between cancer cells and immune cells may enhance the growth of cancer cells (108). Depletion of TRIP13 facilitates activation of immune responses in the tumor microenvironment (35), which improves anticancer treatment resistance. In immune cells, it is important to discover the genes controlled by the TRIP13 protein to develop potential immunotherapeutic targets.
TRIP13 inhibitor resistance may develop in future. Because of this, it will be required to identify genes that confer resistance to TRIP13 inhibitors as well as genes controlled by TRIP13 inhibitors. It is possible that immune evasion, drug efflux, the overexpression of oncogenes and the downregulation of tumor suppressor genes mediate resistance to TRIP13 inhibitors.
Acknowledgements
The authors would like to thank Dr Peng Zhao (Universiti Pendidikan Sultan Idris, Tanjong Malim, Malaysia) for critical review of manuscript.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
LZ, NJ and SY wrote the manuscript. TH and YJG performed the literature review and edited the manuscript. All authors have read and approved the final manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesJeongHWieMBaekIJSohnGUmSHLeeSGSeoYRaJLeeEAKimSTRIP13 participates in immediate-early sensing of DNA strand breaks and ATM signaling amplification through MRE11Cells114095202210.3390/cells1124409536552858LeeJWChoiHSGyurisJBrentRMooreDDTwo classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptorMol Endocrinol9243254199510.1210/mend.9.2.77769747776974San-SegundoPARoederGSPch2 links chromatin silencing to meiotic checkpoint controlCell97313324199910.1016/S0092-8674(00)80741-210319812MiaoCTangDZhangHWangMLiYTangSYuHGuMChengZCentral region component1, a novel synaptonemal complex component, is essential for meiotic recombination initiation in ricePlant Cell2529983009201310.1105/tpc.113.11317523943860FarmerSHongEJLeungWKArgunhanBTerentyevYHumphryesNToyoizumiHTsubouchiHBudding yeast Pch2, a widely conserved meiotic protein, is involved in the initiation of meiotic recombinationPLoS One7e39724201210.1371/journal.pone.003972422745819JoyceEFMcKimKSDrosophila PCH2 is required for a pachytene checkpoint that monitors double-strand-break-independent events leading to meiotic crossover formationGenetics1813951200910.1534/genetics.108.09311218957704YeQRosenbergSCMoellerASpeirJASuTYCorbettKDTRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 conformation switchingElife4e07367201510.7554/eLife.0736725918846LiXCSchimentiJCMouse pachytene checkpoint 2 (trip13) is required for completing meiotic recombination but not synapsisPLoS Genet3e130200710.1371/journal.pgen.003013017696610RoigIDowdleJATothAde RooijDGJasinMKeeneySMouse TRIP13/PCH2 is required for recombination and normal higher-order chromosome structure during meiosisPLoS Genet6e1001062201010.1371/journal.pgen.100106220711356WojtaszLDanielKRoigIBolcun-FilasEXuHBoonsanayVEckmannCRCookeHJJasinMKeeneySMouse HORMAD1 and HORMAD2, two conserved meiotic chromosomal proteins, are depleted from synapsed chromosome axes with the help of TRIP13 AAA-ATPasePLoS Genet5e1000702200910.1371/journal.pgen.100070219851446TiptonARWangKOladimejiPSufiSGuZLiuSTIdentification of novel mitosis regulators through data mining with human centromere/kinetochore proteins as group queriesBMC Cell Biol1315201210.1186/1471-2121-13-1522712476WangKSturt-GillespieBHittleJCMacdonaldDChanGKYenTJLiuSTThyroid hormone receptor interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic checkpoint-silencing proteinJ Biol Chem2892392823937201410.1074/jbc.M114.58531525012665EytanEWangKMiniowitz-ShemtovSSitry-ShevahDKaisariSYenTJLiuSTHershkoADisassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet)Proc Natl Acad Sci USA1111201912024201410.1073/pnas.141290111125092294SilvaRDMirkovicMGuilgurLGRathoreOSMartinhoRGOliveiraRAAbsence of the spindle assembly checkpoint restores mitotic fidelity upon loss of sister chromatid cohesionCurr Biol2828372844.e2833201810.1016/j.cub.2018.06.06230122528BhallaNDernburgAFA conserved checkpoint monitors meiotic chromosome synapsis in Caenorhabditis elegansScience31016831686200510.1126/science.111746816339446BörnerGVBarotAKlecknerNYeast Pch2 promotes domainal axis organization, timely recombination progression, and arrest of defective recombinosomes during meiosisProc Natl Acad Sci USA10533273332200810.1073/pnas.071186410518305165JoshiNBarotAJamisonCBörnerGVPch2 links chromosome axis remodeling at future crossover sites and crossover distribution during yeast meiosisPLoS Genet5e1000557200910.1371/journal.pgen.100055719629172VaderGBlitzblauHGTameMAFalkJECurtinLHochwagenAProtection of repetitive DNA borders from self-induced meiotic instabilityNature477115119201110.1038/nature1033121822291VaderGPch2(TRIP13): Controlling cell division through regulation of HORMA domainsChromosoma124333339201510.1007/s00412-015-0516-y25895724ChenCJomaaAOrtegaJAlaniEEPch2 is a hexameric ring ATPase that remodels the chromosome axis protein Hop1Proc Natl Acad Sci USA111E44E53201424367111YedidiRSWendlerPEnenkelCAAA-ATPases in protein degradationFront Mol Biosci442201710.3389/fmolb.2017.0004228676851ShengNYanLWuKYouWGongJHuLTanGChenHWangZTRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancerCell Death Dis9402201810.1038/s41419-018-0434-z29540729KuritaKMaedaMMansourMAKokuryoTUeharaKYokoyamaYNaginoMHamaguchiMSengaTTRIP13 is expressed in colorectal cancer and promotes cancer cell invasionOncol Lett1252405246201610.3892/ol.2016.533228105232AgarwalSBehringMKimHGChandrashekarDSChakravarthiBVSKGuptaNBajpaiPElkholyAAl DiffalhaSDattaPKTRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability statusMol Oncol1430073029202010.1002/1878-0261.1282133037736BanerjeeRRussoNLiuMBasrurVBellileEPalanisamyNScanlonCSvan TubergenEInglehartRCMetwallyTTRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancerNat Commun54527201410.1038/ncomms552725078033LanJHuangJTaoXGaoYZhangLHuangWLuoJLiuCDengYLiuLLiuXEvaluation of the TRIP13 level in breast cancer and insights into potential molecular pathwaysJ Cell Mol Med2626732685202210.1111/jcmm.1727835322916LiuLZhangZXiaXLeiJKIF18B promotes breast cancer cell proliferation, migration and invasion by targeting TRIP13 and activating the Wnt/β-catenin signaling pathwayOncol Lett23112202210.3892/ol.2022.1323235251343LiZHLeiLFeiLRHuangWJZhengYWYangMQWangZLiuCCXuHTTRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transitionJ Mol Histol521120202110.1007/s10735-020-09919-z33128167CaiWNiWJinYLiYTRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signalingCancer Biomark30237248202110.3233/CBM-20003933136091ZhangQDongYHaoSTongYLuoQAerxidingPThe oncogenic role of TRIP13 in regulating proliferation, invasion, and cell cycle checkpoint in NSCLC cellsInt J Clin Exp Pathol1233573366201931934178YaoJZhangXLiJZhaoDGaoBZhouHGaoSZhangLSilencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF-β1/smad3Cancer Cell Int18208201810.1186/s12935-018-0704-y30564064GarciaMRMeissburgerBChanJde GuiaRMMattijssenFRoesslerSBirkenfeldALRaschzokNRiolsFTokarzJTrip13 depletion in liver cancer induces a lipogenic response contributing to plin2-dependent mitotic cell deathAdv Sci (Weinh)9e2104291202210.1002/advs.20210429136031387DongLDingHLiYXueDLiZLiuYZhangTZhouJWangPTRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancerInt J Biol Macromol121200206201910.1016/j.ijbiomac.2018.09.16830267820ZengLLiuYMYangNZhangTXieHHsa_circRNA_100146 promotes prostate cancer progression by upregulating TRIP13 via sponging miR-615-5pFront Mol Biosci8693477202110.3389/fmolb.2021.69347734307457WangYHuangJLiBXueHTricotGHuLXuZSunXChangSGaoLA small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progressionCancer Res80536548202010.1158/0008-5472.CAN-18-398731732653GaoYLiuSGuoQZhangSZhaoYWangHLiTGongYWangYZhangTIncreased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathwayInt J Biol Sci1514881499201910.7150/ijbs.3271831337978MohammedaIAliME-HMohamedFEAAbd-ElrehimDMImmunohistochemical expression of TRIP13 in transitional and squamous cell carcinoma of urinary bladder carcinomaMinia J Med Res202310.21608/mjmr.2023.189765.1317ZhouKSZhangQZhangWTLiuYYWuSSZhouJWeiXDSongYPStudy on the expression of TRIP13 mRNA in chronic lymphocytic leukemia B lymphocyte and the molecular mechanism of TRIP13 mediated JVM-2 cell proliferation and apoptosisZhonghua Xue Ye Xue Za Zhi386186222017(In Chinese)28810332LiWZhangGLiXWangXLiQHongLShenYZhaoCGongXChenYZhouJThyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinomaBiochem Biophys Res Commun499416424201810.1016/j.bbrc.2018.03.12929567476JuLLiXShaoJLuRWangYBianZUpregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinomaOncol Rep4037943802201830542731LuWMengxuanZMingRZixuGYongZSiminZYangYLeqiQKangjieSYanlinLTRIP13/FLNA complex promotes tumor progression and is associated with unfavorable outcomes in melanomaJ Oncol20221419179202210.1155/2022/141917936268276TaoYYangGYangHSongDHuLXieBWangHGaoLGaoMXuHTRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myelomaOncotarget82671826731201710.18632/oncotarget.1495728157697ZhangLTKeLXWuXYTianHTDengHZXuLYLiEMLongLTRIP13 induces nedaplatin resistance in esophageal squamous cell carcinoma by enhancing repair of DNA damage and inhibiting apoptosisBiomed Res Int20227295458202235601150XuHMaZMoXChenXXuFWuFChenHZhouGXiaHZhangCInducing synergistic DNA damage by TRIP13 and PARP1 inhibitors provides a potential treatment for hepatocellular carcinomaJ Cancer1322262237202210.7150/jca.6602035517402YeQKimDHDereliIRosenbergSCHagemannGHerzogFTóthAClevelandDWCorbettKDThe AAA+ ATPase TRIP13 remodels HORMA domains through N-terminal engagement and unfoldingEMBO J3624192434201710.15252/embj.20179729128659378MapelliMMassimilianoLSantaguidaSMusacchioAThe Mad2 conformational dimer: Structure and implications for the spindle assembly checkpointCell131730743200710.1016/j.cell.2007.08.04918022367MarksDHThomasRChinYShahRKhooCBenezraRMad2 overexpression uncovers a critical role for TRIP13 in mitotic exitCell Rep1918321845201710.1016/j.celrep.2017.05.02128564602YangMLiBTomchickDRMachiusMRizoJYuHLuoXp31comet blocks Mad2 activation through structural mimicryCell131744755200710.1016/j.cell.2007.08.04818022368RosenbergSCCorbettKDThe multifaceted roles of the HORMA domain in cellular signalingJ Cell Biol211745755201510.1083/jcb.20150907626598612ZhouKZhangWZhangQGuiRZhaoHChaiXLiYWeiXSongYLoss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemiaOncotarget82546925481201710.18632/oncotarget.1603828424416FurlongFFitzpatrickPO'TooleSPhelanSMcGroganBMaguireAO'GradyAGallagherMPrencipeMMcGoldrickALow MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancerJ Pathol226746755201210.1002/path.303522069160ZhouXYShuXMTRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathwayEur Rev Med Pharmacol Sci23522529201930720159AmawiHSimHMTiwariAKAmbudkarSVShuklaSABC transporter-mediated multidrug-resistant cancerAdv Exp Med Biol1141549580201910.1007/978-981-13-7647-4_1231571174KhatamiMCancer; an induced disease of twentieth century! Induction of tolerance, increased entropy and ‘Dark Energy’: Loss of biorhythms (Anabolism v. Catabolism)Clin Transl Med720201810.1186/s40169-018-0193-629961900WangDCWangWZhuBWangXLung cancer heterogeneity and new strategies for drug therapyAnnu Rev Pharmacol Toxicol58531546201810.1146/annurev-pharmtox-010716-10452328977762BukowskiKKciukMKontekRMechanisms of multidrug resistance in cancer chemotherapyInt J Mol Sci213233202010.3390/ijms2109323332370233VasanNBaselgaJHymanDMA view on drug resistance in cancerNature575299309201910.1038/s41586-019-1730-131723286LuSGuoMFanZChenYShiXGuCYangYElevated TRIP13 drives cell proliferation and drug resistance in bladder cancerAm J Transl Res1143974410201931396344LiCXiaJFranqui-MachinRChenFHeYAshbyTCTengFXuHLiuDGaiDTRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignanciesJ Clin Invest131e146893202110.1172/JCI14689334061780OzolsRFYoungRCHigh-dose cisplatin therapy in ovarian cancerSemin Oncol12213019853909419MarkmanMIntraperitoneal cisplatin and carboplatin in the management of ovarian cancerSemin Oncol211719quiz 205819948202717ZońABednarekICisplatin in ovarian cancer treatment-known limitations in therapy force new solutionsInt J Mol Sci247585202310.3390/ijms2408758537108749MitticaGGhisoniEGiannoneGGentaSAgliettaMSapinoAValabregaGPARP inhibitors in ovarian cancerRecent Pat Anticancer Drug Discov13392410201810.2174/157489281366618030516525629512470SmithMPothuriBAppropriate selection of PARP inhibitors in ovarian cancerCurr Treat Options Oncol23887903202210.1007/s11864-022-00938-435412195JiangXLiXLiWBaiHZhangZPARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanismsJ Cell Mol Med2323032313201910.1111/jcmm.1413330672100MusacchioASalmonEDThe spindle-assembly checkpoint in space and timeNat Rev Mol Cell Biol8379393200710.1038/nrm216317426725Lara-GonzalezPWesthorpeFGTaylorSSThe spindle assembly checkpointCurr Biol22R966R980201210.1016/j.cub.2012.10.00623174302ChaoWCKulkarniKZhangZKongEHBarfordDStructure of the mitotic checkpoint complexNature484208213201210.1038/nature1089622437499de CárcerGMalumbresMA centrosomal route for cancer genome instabilityNat Cell Biol16504506201410.1038/ncb297824875738SotilloRSchvartzmanJMSocciNDBenezraRMad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalNature464436440201010.1038/nature0880320173739Bargiela-IparraguirreJPrado-MarchalLPajuelo-LozanoNJiménezBPeronaRSánchez-PérezIMad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cellsCell Cycle1335903601201410.4161/15384101.2014.96295225483095TusellLPampalonaJSolerDFríasCGenescàADifferent outcomes of telomere-dependent anaphase bridgesBiochem Soc Trans3816981703201010.1042/BST038169821118150StewéniusYGorunovaLJonsonTLarssonNHöglundMMandahlNMertensFMitelmanFGisselssonDStructural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarityProc Natl Acad Sci USA10255415546200510.1073/pnas.040845410215809428BaileySMMurnaneJPTelomeres, chromosome instability and cancerNucleic Acids Res3424082417200610.1093/nar/gkl30316682448MillsKDFergusonDOAltFWThe role of DNA breaks in genomic instability and tumorigenesisImmunol Rev1947795200310.1034/j.1600-065X.2003.00060.x12846809ZhouWYangYXiaJWangHSalamaMEXiongWXuHShettySChenTZengZNEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancersCancer Cell234862201310.1016/j.ccr.2012.12.00123328480CarterSLEklundACKohaneISHarrisLNSzallasiZA signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNat Genet3810431048200610.1038/ng186116921376ClairmontCSSarangiPPonnienselvanKGalliLDCseteIMoreauLAdelmantGChowdhuryDMartoJAD'AndreaADTRIP13 regulates DNA repair pathway choice through REV7 conformational changeNat Cell Biol228796202010.1038/s41556-019-0442-y31915374SudakinVChanGKYenTJCheckpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2J Cell Biol154925936200110.1083/jcb.20010209311535616OverlackKBangeTWeissmannFFaesenACMaffiniSPrimoracIMüllerFPetersJMMusacchioABubR1 promotes Bub3-dependent APC/C inhibition during spindle assembly checkpoint signalingCurr Biol2729152927.e2917201710.1016/j.cub.2017.08.03328943088BurtonJLSolomonMJMad3p, a pseudosubstrate inhibitor of APCCdc20 in the spindle assembly checkpointGenes Dev21655667200710.1101/gad.151110717369399McGranahanNBurrellRAEndesfelderDNovelliMRSwantonCCancer chromosomal instability: Therapeutic and diagnostic challengesEMBO Rep13528538201210.1038/embor.2012.6122595889LischettiTNilssonJRegulation of mitotic progression by the spindle assembly checkpointMol Cell Oncol2e970484201510.4161/23723548.2014.97048427308407SudoTNittaMSayaHUenoNTDependence of paclitaxel sensitivity on a functional spindle assembly checkpointCancer Res6425022508200410.1158/0008-5472.CAN-03-201315059905WangMChenSAoDTargeting DNA repair pathway in cancer: Mechanisms and clinical applicationMedComm20202654691202110.1002/mco2.10334977872HanahanDWeinbergRAThe hallmarks of cancerCell1005770200010.1016/S0092-8674(00)81683-910647931HanahanDWeinbergRAHallmarks of cancer: The next generationCell144646674201110.1016/j.cell.2011.02.01321376230DengSVlatkovicTLiMZhanTVeldwijkMRHerskindCTargeting the DNA damage response and DNA repair pathways to enhance radiosensitivity in colorectal cancerCancers (Basel)144874202210.3390/cancers1419487436230796MirzaMRPignataSLedermannJALatest clinical evidence and further development of PARP inhibitors in ovarian cancerAnn Oncol2913661376201810.1093/annonc/mdy17429750420SchettiniFGiudiciFBernocchiOSiricoMCoronaSPGiulianoMLocciMParisIScambiaGDe PlacidoSPoly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysisEur J Cancer149134152202110.1016/j.ejca.2021.02.03533862496TuttANJGarberJEKaufmanBVialeGFumagalliDRastogiPGelberRDde AzambujaEFieldingABalmañaJAdjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancerN Engl J Med38423942405202110.1056/NEJMoa210521534081848CarreiraSPortaNArce-GallegoSSeedGLlop-GuevaraABianchiniDRescignoPPaschalisABertanCBakerCBiomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trialCancer Discov1128122827202110.1158/2159-8290.CD-21-000734045297MateoJPortaNBianchiniDMcGovernUElliottTJonesRSyndikusIRalphCJainSVarugheseMOlaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): A multicentre, open-label, randomised, phase 2 trialLancet Oncol21162174202010.1016/S1470-2045(19)30684-931806540MaughanBLAntonarakisESOlaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancerExpert Opin Pharmacother2216251632202110.1080/14656566.2021.191201533827356ClearyJMWolpinBMDouganSKRaghavanSSinghHHuffmanBSethiNSNowakJAShapiroGIAguirreAJD'AndreaADOpportunities for utilization of DNA repair inhibitors in homologous recombination repair-deficient and proficient pancreatic adenocarcinomaClin Cancer Res2766226637202110.1158/1078-0432.CCR-21-136734285063van WaardenburgRYangESTargeting DNA repair pathways to overcome cancer drug resistanceCancer Drug Resist4837841202134532658GhoshSMazumdarTXuWPowellRTStephanCShenLShahPAPickeringCRMyersJNWangJCombined TRIP13 and aurora kinase inhibition induces apoptosis in human papillomavirus–driven cancersClin Cancer Res2844794493202210.1158/1078-0432.CCR-22-162735972731ChangHZouZTargeting autophagy to overcome drug resistance: Further developmentsJ Hematol Oncol13159202010.1186/s13045-020-01000-233239065Ahmadi-DehlaghiFMohammadiPValipourEPournaghiPKianiSMansouriKAutophagy: A challengeable paradox in cancer treatmentCancer Med121154211569202310.1002/cam4.557736760166Salimi-JedaAGhabeshiSPourZGMJazaeriEOAraiinejadMSheikholeslamiFAbdoliMEdalatMAbdoliAAutophagy modulation and cancer combination therapy: A smart approach in cancer therapyCancer Treat Res Commun30100512202210.1016/j.ctarc.2022.10051235026533LevineBKroemerGBiological functions of autophagy genes: A disease perspectiveCell1761142201910.1016/j.cell.2018.09.04830633901GalluzziLGreenDRAutophagy-independent functions of the autophagy machineryCell17716821699201910.1016/j.cell.2019.05.02631199916DikicIElazarZMechanism and medical implications of mammalian autophagyNat Rev Mol Cell Biol19349364201810.1038/s41580-018-0003-429618831WuMZhangPEGFR-mediated autophagy in tumourigenesis and therapeutic resistanceCancer Lett469207216202010.1016/j.canlet.2019.10.03031639425LiYJLeiYHYaoNWangCRHuNYeWCZhangDMChenZSAutophagy and multidrug resistance in cancerChin J Cancer3652201710.1186/s40880-017-0219-228646911AmaravadiRKKimmelmanACDebnathJTargeting autophagy in cancer: Recent advances and future directionsCancer Discov911671181201910.1158/2159-8290.CD-19-029231434711XiaoZLiMZhangXRongXXuHTRIP13 overexpression promotes gefitinib resistance in non-small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathwayOncol Rep4984202310.3892/or.2023.852136896765SharmaPHu-LieskovanSWargoJARibasAPrimary, adaptive, and acquired resistance to cancer immunotherapyCell168707723201710.1016/j.cell.2017.01.01728187290AgarwalSAfaqFBajpaiPKimHGElkholyABehringMChandrashekarDSDiffalhaSAKhushmanMSugandhaSPDCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancerMol Oncol1617281745202210.1002/1878-0261.1320135194944QieSDiehlJACyclin D1, cancer progression, and opportunities in cancer treatmentJ Mol Med (Berl)9413131326201610.1007/s00109-016-1475-327695879LindahlTBarnesDERepair of endogenous DNA damageCold Spring Harb Symp Quant Biol65127133200010.1101/sqb.2000.65.12712760027SarangiPClairmontCSGalliLDMoreauLAD'AndreaADp31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPaseProc Natl Acad Sci USA1172679526803202010.1073/pnas.200883011733051298CorbettKDp31comet and TRIP13 recycle Rev7 to regulate DNA repairProc Natl Acad Sci USA1172776127763202010.1073/pnas.202010311733122436OserMGFonsecaRChakrabortyAABroughRSpektorAJenningsRBFlaifelANovakJSGulatiABussECells lacking the RB1 tumor suppressor gene are hyperdependent on aurora B kinase for survivalCancer Discov9230247201910.1158/2159-8290.CD-18-038930373918GongXDuJParsonsSHMerzougFFWebsterYIversenPWChioLCVan HornRDLinXBlosserWAurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor geneCancer Discov9248263201910.1158/2159-8290.CD-18-046930373917SchvartzmanJMDuijfPHSotilloRCokerCBenezraRMad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibitionCancer Cell19701714201110.1016/j.ccr.2011.04.01721665145LiZLiuJChenTSunRLiuZQiuBXuYZhangZHMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-MycJ Exp Clin Cancer Res4086202110.1186/s13046-021-01890-133648560ZhangXZhouJXueDLiZLiuYDongLMiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancerInt J Biol Macromol129227232201910.1016/j.ijbiomac.2019.01.12730685303ChenYChenDQinYQiuCZhouYDaiMLiLSunQJiangYTRIP13, identified as a hub gene of tumor progression, is the target of microRNA-4693-5p and a potential therapeutic target for colorectal cancerCell Death Discov835202210.1038/s41420-022-00824-w35075117ZhuMXWeiCYZhangPFGaoDMChenJZhaoYDongSSLiuBBElevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4J Exp Clin Cancer Res38409201910.1186/s13046-019-1401-y31533816ArunGDiermeierSDSpectorDLTherapeutic targeting of long non-coding RNAs in cancerTrends Mol Med24257277201810.1016/j.molmed.2018.01.00129449148
Structure of human TRIP13/ATP bound form. The 3D structures of TRIP13 protein (PDB: 5VQA) bound with ATP.
The underlying mechanism of TRIP13 mediated anticancer drug. There are primarily three molecular mechanisms involved in TRIP13-mediated drug resistance. These mechanisms include promoting chromosomal instability, enhancing autophagy, and modulating the tumor microenvironment resistance. MCC, mitotic checkpoint complex, PUMA: p53 upregulated modulator of apoptosis.
Combination of TRIP13 and TRIP13 depletion inhibitors and other drugs.
Treatment
TRIP13 effect
Pharmacological interaction
Tumor
First author (year)
(Refs.)
DCZ0415 with PARP1 inhibitor Olaparib
Impaired DNA repair gene regulation and expression
Synergistic
Hepatocellular Carcinoma
Xu et al (2022)
[44] J Cancer (2022) 13 (7): 2226–2237.
Combining Aurora kinase inhibition with TRIP13 depletion
Led to extensive apoptosis
Synergistic
HPV-negative cancer cells
Soma Ghosh et al (2022)
[97] Clin Cancer Res (2022) 28 (20): 4479–4493.
DCZ0415 with the multiple myeloma chemotherapeutic melphalan
Impaired nonhomologous end joining repair and inhibited NF-κB activity
Synergistic
Multiple Myeloma
Yingcong Wang et al (2020)
[35] Cancer Res (2020) 80 (3): 536–548.
DCZ0415 with the HDAC inhibitor Panobinostat
Impaired nonhomologous end joining repair and inhibited NF-κB activity
Synergistic
Multiple Myeloma
Yingcong Wang et al (2020)
[35] Cancer Res (2020) 80 (3): 536–548.
Combining the DNA-PKcs inhibitor Nu7026 with TRIP13 depletion
TRIP13 provides the energy needed for assembly of the DNA-PKcs complex
Synergistic
Head and neck cancer
Rajat Banerjee et al (2014)
[25] Nat Commun. 2014; 5: 4527.
TRIP13, thyroid hormone receptor interactor 13; DCZ0415, a small-molecule inhibitor targeting TRIP13; PARP1, poly(ADP-ribose) polymerase 1; Olaparib, an inhibitor of the enzyme poly ADP ribose polymerase (PARP); DNA, deoxyribonucleic acid; HPV, Human papillomavirus; NF-κB, Nuclear factor kappa-light-chain-enhancer of activated B cells; HDAC, Histone deacetylases; DNA-PKcs, DNA-dependent protein kinase, catalytic subunit; Nu7026, a potent DNA-PK inhibitor